تداخلات سيفازولين

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (نشرة إرتابينيم، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. (نشرة إيميبينيم وسيلاستاتين، التحذيرات والاحتياطات)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (نشرة سيفازولين، التداخلات الدوائية)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (نشرة سيفازولين، التداخلات الدوائية)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (نشرة ريفامبيسين، التحذيرات)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (نشرة سيفازولين، موانع الاستعمال)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (نشرة أزتريونام، التحذيرات والاحتياطات)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Drug Interactions Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see DOSAGE AND ADMINISTRATION ). (نشرة بروتامين، الاحتياطات)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. (نشرة جنتاميسين، التداخلات الدوائية)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (نشرة حمض الإيثاكرينيك، التداخلات الدوائية)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. (نشرة فوروسيميد، التداخلات الدوائية)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (نشرة سيفازولين، التحذيرات والاحتياطات)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (نشرة سيفازولين، التحذيرات والاحتياطات)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (نشرة ميكوفينولات، التداخلات الدوائية)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. (نشرة أمينوفيلين، التداخلات الدوائية)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Some drugs (e.g. cefazolin, cephalothin), however, may interfere with certain HPLC techniques. (نشرة ثيوفيلين، التداخلات الدوائية)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (نشرة سيفازولين، التحذيرات والاحتياطات)

Before initiating therapy with Meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. (نشرة ميروبينيم، التحذيرات والاحتياطات)